1,577 results match your criteria Cardiovascular Diabetology[Journal]


sRAGE and early signs of cardiac target organ damage in mild hypertensives.

Cardiovasc Diabetol 2019 Feb 12;18(1):17. Epub 2019 Feb 12.

Interdepartimental Center for Research in Molecular Medicine (CIRMC), University of Pavia, Pavia, Italy.

Background: Soluble Receptor for Advanced Glycation End Products (sRAGE) may be considered a marker inversely related to inflammation and its participation has been established in patients with advanced atherosclerotic vascular diseases. However, it is still unknown whether sRAGE reduction could be early metabolic change in the first stage of hypertension and initial hypertension-associated cardiac damage. We sought to determine the sRAGE values in otherwise healthy, untreated and recently diagnosed mild hypertensives and evaluate their association with blood pressure (BP) values, metabolic parameters, and with subclinical initial signs of cardiac target organ damage (TOD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0821-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371567PMC
February 2019

SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob mice.

Cardiovasc Diabetol 2019 Feb 7;18(1):16. Epub 2019 Feb 7.

Bioscience, Cardiovascular, Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal, 431 83, Gothenburg, Sweden.

Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) is the first class of anti-diabetes treatment that reduces mortality and risk for hospitalization due to heart failure. In clinical studies it has been shown that SGLT2i's promote a general shift to fasting state metabolism characterized by reduced body weight and blood glucose, increase in glucagon/insulin ratio and modest increase in blood ketone levels. Therefore, we investigated the connection between metabolic changes and cardiovascular function in the ob/ob mice; a rodent model of early diabetes with specific focus on coronary microvascular function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0820-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366096PMC
February 2019

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.

Cardiovasc Diabetol 2019 Feb 2;18(1):15. Epub 2019 Feb 2.

NHC Key Laboratory of Hormones and Development (Tianjin Medical University), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University Metabolic Diseases Hospital & Tianjin Institute of Endocrinology, Tianjin, 300070, China.

Background: Hyperglycaemia associated with myocardial oxidative stress and fibrosis is the main cause of diabetic cardiomyopathy. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor has recently been reported to improve glycaemic control in patients with type 2 diabetes in an insulin-independent manner. The aim of this study was to investigate the effect of empagliflozin on myocardium injury and the potential mechanism in type 2 diabetic KK-Ay mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0816-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359811PMC
February 2019
1 Read

Comparative effects of lipid lowering, hypoglycemic, antihypertensive and antiplatelet medications on carotid artery intima-media thickness progression: a network meta-analysis.

Cardiovasc Diabetol 2019 Jan 30;18(1):14. Epub 2019 Jan 30.

Department of Cardiothoracic Surgery, The First People's Hospital of Yunnan Province, Kunming, Yunnan, China.

Background: Carotid artery intima-media thickness (cIMT) progression is a surrogate marker of atherosclerosis with a high predictive value for future CVD risk. This study evaluates the comparative efficacies of lipid lowering, hypoglycemic, antihypertensive and antiplatelet medications on cIMT progression.

Methods: We conducted a network meta-analysis (NMA) to evaluate the relative efficacies of several drug classes in modifying cIMT progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0817-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352423PMC
January 2019

Early dysregulation of cardiac-specific microRNA-208a is linked to maladaptive cardiac remodelling in diabetic myocardium.

Cardiovasc Diabetol 2019 Jan 29;18(1):13. Epub 2019 Jan 29.

Department of Physiology-HeartOtago, Otago School of Medical Sciences, University of Otago, 270, Great King Street, Dunedin, 9010, New Zealand.

Background: The diabetic heart undergoes remodelling contributing to an increased incidence of heart failure in individuals with diabetes at a later stage. The molecular regulators that drive this process in the diabetic heart are still unknown.

Methods: Real-time (RT) PCR analysis was performed to determine the expression of cardiac specific microRNA-208a in right atrial appendage (RAA) and left ventricular (LV) biopsy tissues collected from diabetic and non-diabetic patients undergoing coronary artery bypass graft surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0814-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352455PMC
January 2019

Remnant lipoproteins play an important role of in-stent restenosis in type 2 diabetes undergoing percutaneous coronary intervention: a single-centre observational cohort study.

Cardiovasc Diabetol 2019 Jan 28;18(1):11. Epub 2019 Jan 28.

Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotlic Disease, Clinical Centre for Coronary Heart Disease, No. 2 Anzhen Road, Chaoyang District, Beijing, 100029, China.

Background: Increasing evidence has suggested that the presence of remnant lipoproteins is a significant risk factor for atherosclerosis. Remnant lipoproteins are lipoproteins that are rich in triglycerides (TGs), and the main components include very-low-density lipoprotein (VLDL) in the fasting state. Diabetic patients often have hypertriglyceridemia with elevated levels of VLDL cholesterol but normal levels of low-density lipoprotein cholesterol (LDL-C). Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-019-0819-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348605PMC
January 2019
4 Reads

Concerns about clinical efficacy and safety of warfarin in diabetic patients with atrial fibrillation.

Cardiovasc Diabetol 2019 Jan 28;18(1):12. Epub 2019 Jan 28.

Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, 830-0011, Japan.

Atrial fibrillation (AF) is one of the most common arrhythmias in elderly people. The risk of thromboembolic stroke is increased in AF patients, especially those with diabetes. Anticoagulant therapy, such as warfarin and non-vitamin K oral anticoagulants (NOACs), is recommended for diabetic patients with AF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0818-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348611PMC
January 2019

PDM-ProValue meets cardiovascular outcome trials in diabetes.

Cardiovasc Diabetol 2019 Jan 28;18(1):10. Epub 2019 Jan 28.

Forschergruppe Diabetes e.V., Muenchen-Neuherberg, Germany.

Novel studies have increased our knowledge regarding optimal treatment options in diabetes. Key studies that have broadened our knowledge about optimal treatment options in diabetes in recent years are cardiovascular outcome trials (CVOTs) and studies investigating aspects of digitalisation and monitoring of glucose (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0815-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348620PMC
January 2019

Developmental trajectories of body mass index from childhood into late adolescence and subsequent late adolescence-young adulthood cardiometabolic risk markers.

Cardiovasc Diabetol 2019 Jan 19;18(1). Epub 2019 Jan 19.

Nutritional Epidemiology, DONALD Study, Department of Nutrition and Food Sciences, Rheinische Friedrich-Wilhelms-University Bonn, Bonn, Germany.

Background: Reports on body mass index (BMI) trajectories from childhood into late adolescence, their determinants, and subsequent cardiometabolic risk markers, particularly among European populations have been few. Moreover, sex-specific investigation is necessary considering the sex difference in BMI, and the sex-specific association between BMI and some cardiometabolic risk markers.

Methods: Using a sample from the DOrtmund Nutritional and Anthropometric Longitudinally Designed study, we explored sex-specific trajectories of the BMI standard deviation score (SDS) from 4 to 18 years of age in 354 males and 335 females by latent (class) growth models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0813-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339359PMC
January 2019
2 Reads

MiR-30c/PGC-1β protects against diabetic cardiomyopathy via PPARα.

Cardiovasc Diabetol 2019 Jan 11;18(1). Epub 2019 Jan 11.

Division of Cardiology and Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.

Background: Metabolic abnormalities have been implicated as a causal event in diabetic cardiomyopathy (DCM). However, the mechanisms underlying cardiac metabolic disorder in DCM were not fully understood.

Results: Db/db mice, palmitate treated H9c2 cells and primary neonatal rat cardiomyocytes were employed in the current study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0811-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329097PMC
January 2019
2 Reads

Association between serum haptoglobin and carotid arterial functions: usefulness of a targeted metabolomics approach.

Cardiovasc Diabetol 2019 Jan 11;18(1). Epub 2019 Jan 11.

Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Clinical Center for Diabetes, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai, 200233, People's Republic of China.

Background: Serum haptoglobin (Hp) has been closely associated with cardio-cerebrovascular diseases. We investigated a metabolic profile associated with circulating Hp and carotid arterial functions via a targeted metabolomics approach to provide insight into potential mechanisms.

Methods: A total of 240 participants, including 120 patients with type 2 diabetes mellitus (T2DM) and 120 non-diabetes mellitus (non-DM) subjects were recruited in this study. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-019-0808-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329046PMC
January 2019
5 Reads

Improved outcome of patients with diabetes mellitus with good glycemic control in the cardiac intensive care unit: a retrospective study.

Cardiovasc Diabetol 2019 Jan 11;18(1). Epub 2019 Jan 11.

Diabetes Unit, Wolfson Medical Center, Holon, Israel.

Background: Diabetes mellitus (DM) is a prevalent metabolic disease characterized by chronic hyperglycemia. A primary burden of DM is related to its long-term complications, which have been shown to impact the course of hospitalization and to influence patients' outcome.

Aim: To assess the role of in-hospital glucose control on length of stay, 30-days and 1-year mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0810-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329158PMC
January 2019
1 Read

Sortilin levels are associated with peripheral arterial disease in type 2 diabetic subjects.

Cardiovasc Diabetol 2019 Jan 11;18(1). Epub 2019 Jan 11.

U.O.C. Clinica Medica e Malattie Vascolari, Department of Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo F. Vito 1, 00168, Rome, Italy.

Background: Sortilin is a 95-kDa protein which has recently been linked to circulating cholesterol concentration and lifetime risk of developing significant atherosclerotic disease. Sortilin is found inside different cell types and circulating in blood. Higher circulating sortilin concentration has been found in patients with coronary atherosclerosis compared to control subjects. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-019-0805-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329108PMC
January 2019
7 Reads

Reduction in the incidence of myocardial infarction with sodium-glucose linked cotransporter-2 inhibitors: evident and plausible.

Cardiovasc Diabetol 2019 Jan 11;18(1). Epub 2019 Jan 11.

Division of Cardiology, St. Michael's Hospital, 30 Bond Street, Toronto, ON, M5B 1W8, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0812-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329062PMC
January 2019
1 Read

Prognostic impact of carotid intima-media thickness and carotid plaques on the development of micro- and macrovascular complications in individuals with type 2 diabetes: the Rio de Janeiro type 2 diabetes cohort study.

Cardiovasc Diabetol 2019 Jan 10;18(1). Epub 2019 Jan 10.

Department of Internal Medicine, School of Medicine, University Hospital Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rua Rodolpho Rocco, 255, Cidade Universitária, Rio de Janeiro, CEP 21941-913, Brazil.

Background: The prognostic importance of carotid atherosclerosis in individuals with diabetes is unsettled. We aimed to evaluate the relationships between parameters of carotid atherosclerosis and the future occurrence of micro- and cardiovascular complications in individuals with type 2 diabetes.

Methods: Ultrasonographic parameters of carotid atherosclerosis, intima-media thickness (CIMT) and plaques, were measured at baseline in 478 participants who were followed-up for a median of 10. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0809-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327523PMC
January 2019
2 Reads

Epicardial fat tissue in patients with diabetes mellitus: a systematic review and meta-analysis.

Cardiovasc Diabetol 2019 Jan 10;18(1). Epub 2019 Jan 10.

Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.

Background: Epicardial fat tissue (EFT) is the visceral fat distributed along the coronary arteries between the pericardium and the myocardium. Increases in EFT are closely related to the occurrence of diabetes mellitus (DM) and cardiovascular disease. To further understand the link between EFT and DM, we conducted a meta-analysis of the relevant literature. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-019-0807-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327515PMC
January 2019
5 Reads

Targeting the glucagon receptor improves cardiac function and enhances insulin sensitivity following a myocardial infarction.

Cardiovasc Diabetol 2019 Jan 9;18(1). Epub 2019 Jan 9.

Cardiovascular Research Centre, 423 Heritage Medical Research Centre, University of Alberta, Edmonton, AB, T6G 2S2, Canada.

Background: In heart failure the myocardium becomes insulin resistant which negatively influences cardiac energy metabolism and function, while increasing cardiac insulin signalling improves cardiac function and prevents adverse remodelling in the failing heart. Glucagon's action on cardiac glucose and lipid homeostasis counteract that of insulin's action. We hypothesised that pharmacological antagonism of myocardial glucagon action, using a human monoclonal antibody (mAb A) against glucagon receptor (GCGR), a G-protein coupled receptor, will enhance insulin sensitivity and improve cardiac energy metabolism and function post myocardial infarction (MI). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-019-0806-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325856PMC
January 2019
1 Read

A 23-year study of mortality and development of co-morbidities in patients with obesity undergoing bariatric surgery (laparoscopic gastric banding) in comparison with medical treatment of obesity.

Cardiovasc Diabetol 2018 12 29;17(1):161. Epub 2018 Dec 29.

Università degli Studi di Milano, Milan, Italy.

Background And Aim: Several studies have shown that bariatric surgery reduces long term mortality compared to medical weight loss therapy. In a previous study we have demonstrated that gastric banding (LAGB) is associated with reduced mortality in patients with and without diabetes, and with reduced incidence of obesity co-morbidities (cardiovascular disease, diabetes, and cancer) at a 17 year follow-up. The aim of this study was to verify at a longer time interval (23 years) mortality and incidence of co-morbidities in patients undergoing LAGB or medical weight loss therapy. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-018-0801-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311074PMC
December 2018
8 Reads

Alogliptin prevents diastolic dysfunction and preserves left ventricular mitochondrial function in diabetic rabbits.

Cardiovasc Diabetol 2018 12 27;17(1):160. Epub 2018 Dec 27.

Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, No. 23 Pingjiang Road, Hexi District, Tianjin, 300211, People's Republic of China.

Background: There are increasing evidence that left ventricle diastolic dysfunction is the initial functional alteration in the diabetic myocardium. In this study, we hypothesized that alogliptin prevents diastolic dysfunction and preserves left ventricular mitochondrial function and structure in diabetic rabbits.

Methods: A total of 30 rabbits were randomized into control group (CON, n = 10), alloxan-induced diabetic group (DM, n = 10) and alogliptin-treated (12. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0803-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307280PMC
December 2018
2 Reads

Correction to: Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: clinical outcomes at 1-year follow-up.

Cardiovasc Diabetol 2018 12 27;17(1):159. Epub 2018 Dec 27.

Department of Medical, Surgical, Neurological, Aging and Metabolic Sciences, University of Campania "Luigi Vanvitelli", Piazza Miraglia, 2, 80138, Naples, Italy.

Following publication of the original article [1], the authors reported an error in Acknowledgment section. The last sentence should read as "All authors have read and approval the submission to Cardiovascular Diabetology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0804-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307298PMC
December 2018
2 Reads

Low cholesterol efflux capacity and abnormal lipoprotein particles in youth with type 1 diabetes: a case control study.

Cardiovasc Diabetol 2018 12 19;17(1):158. Epub 2018 Dec 19.

Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

Background: Patients with type 1 diabetes (T1DM) have increased mortality from cardiovascular disease (CVD). Risk factors for CVD include an elevation of LDL (LDLp) and small HDL (sHDLp) particles, and a decrease in reverse cholesterol transport i.e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0802-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299549PMC
December 2018
1 Read

GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data.

Cardiovasc Diabetol 2018 12 13;17(1):157. Epub 2018 Dec 13.

Cardiology Division, Pontifical Catholic University of Campinas Medicine School, Rua Engenheiro Carlos Stevenson 560, Campinas, Sao Paulo, 13092-132, Brazil.

Patients with type 2 diabetes (T2DM) have a substantial risk of developing cardiovascular disease. The strong connection between the severity of hyperglycaemia, metabolic changes secondary to T2DM and vascular damage increases the risk of macrovascular complications. There is a challenging demand for the development of drugs that control hyperglycaemia and influence other metabolic risk factors to improve cardiovascular outcomes such as cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina and heart failure (major adverse cardiovascular events). Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-018-0800-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292070PMC
December 2018
7 Reads

Associations between epicardial adipose tissue, subclinical atherosclerosis and high-density lipoprotein composition in type 1 diabetes.

Cardiovasc Diabetol 2018 12 7;17(1):156. Epub 2018 Dec 7.

Cardiovascular Biochemistry Group, Research Institute of the Hospital de la Santa Creu i Sant Pau (IIB Sant Pau), Barcelona, Spain.

Background: The pathophysiology of cardiovascular complications in people with type 1 diabetes (T1DM) remains unclear. An increase in epicardial adipose tissue (EAT) and alterations in the composition of high-density lipoprotein (HDL) are associated with coronary artery disease, but information on its relationship in T1DM is very limited. Our aim was to determine the association between EAT volume, subclinical atherosclerosis, and HDL composition in type 1 diabetes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0794-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284304PMC
December 2018
1 Read

Effect of statins on fasting glucose in non-diabetic individuals: nationwide population-based health examination in Korea.

Cardiovasc Diabetol 2018 12 5;17(1):155. Epub 2018 Dec 5.

Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul, 06273, Republic of Korea.

Background: Increasing evidence suggest that statin therapy has a diabetogenic effect. Individual types of statin may have a different effect on glucose metabolism. Using the repeated nationwide population-based health screening data in Korea, we investigated the longitudinal changes in fasting glucose level of non-diabetic individuals by use of statins. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-018-0799-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280428PMC
December 2018
13 Reads
4.015 Impact Factor

Cognitive function in adolescence and the risk for premature diabetes and cardiovascular mortality in adulthood.

Cardiovasc Diabetol 2018 12 5;17(1):154. Epub 2018 Dec 5.

The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Background: Epidemiological studies have demonstrated a relationship between cognitive function in youth and the future risk of death. Less is known regarding the relationship with diabetes related death. This study assessed the relationship between cognitive function in late adolescence and the risk for diabetes, cardiovascular- (CVD) and all-cause mortality in adulthood. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-018-0798-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280532PMC
December 2018
9 Reads

Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus.

Cardiovasc Diabetol 2018 12 3;17(1):153. Epub 2018 Dec 3.

Department of Vascular Diseases, University Medical Centre Ljubljana, Zaloška Cesta 7, 1000, Ljubljana, Slovenia.

Background: Deteriorated arterial function and high incidence of cardiovascular events characterise diabetes mellitus. Metformin and recent antidiabetic drugs, SGLT2 inhibitors, reduce cardiovascular events. We explored the possible effects of empagliflozin's effect on top of metformin treatment on endothelial function and arterial stiffness parameters in type 1 diabetes mellitus (T1DM) patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0797-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276165PMC
December 2018
2 Reads

Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: clinical outcomes at 1-year follow-up.

Cardiovasc Diabetol 2018 11 29;17(1):152. Epub 2018 Nov 29.

Department of Medical, Surgical, Neurological, Aging and Metabolic Sciences, University of Campania "Luigi Vanvitelli", Piazza Miraglia, 2, 80138, Naples, Italy.

Objectives: We evaluate whether the thrombus aspiration (TA) before primary percutaneous coronary intervention (PPCI) may improve STEMI outcomes in hyperglycemic patients.

Background: The management of hyperglycemic patients during STEMI is unclear.

Methods: We undertook an observational cohort study of 3166 first STEMI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0795-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262961PMC
November 2018
1 Read

Impact of type 2 diabetes mellitus on short- and long-term mortality after coronary artery bypass surgery.

Cardiovasc Diabetol 2018 11 29;17(1):151. Epub 2018 Nov 29.

Department of Cardiac Surgery, Sheba Medical Center, Tel Hashomer, Affiliated to the Sackler School of Medicine, Tel Aviv University, 52621, Tel Aviv, Israel.

Background: Type 2 diabetes mellitus (DM) is a frequent co-morbidity among patients undergoing coronary artery bypass grafting (CABG) surgery. The aim of this study was to evaluate the impact of DM on the early- and long-term outcomes of patients who underwent isolated CABG.

Methods: We performed an observational cohort study in a large tertiary medical center over a period of 11 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0796-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264047PMC
November 2018
1 Read

Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program).

Cardiovasc Diabetol 2018 11 28;17(1):150. Epub 2018 Nov 28.

University of Leicester, University Rd, Leicester, LE1 7RH, UK.

Background: The global prevalence of type 2 diabetes-related complications is not well described. We assessed prevalence of vascular complications at baseline in DISCOVER (NCT02322762; NCT02226822), a global, prospective, observational study program of 15,992 patients with type 2 diabetes initiating second-line therapy, conducted across 38 countries.

Methods: Patients were recruited from primary and specialist healthcare settings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0787-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260731PMC
November 2018
1 Read

Increased glycated albumin and decreased esRAGE levels in serum are related to negative coronary artery remodeling in patients with type 2 diabetes: an Intravascular ultrasound study.

Cardiovasc Diabetol 2018 11 27;17(1):149. Epub 2018 Nov 27.

Department of Cardiology, Rui Jin Hospital, Jiao Tong University School of Medicine, Shanghai, 200025, People's Republic of China.

Background: Negative coronary artery remodeling is frequent in patients with diabetes, but its mechanism remains unclear. We here evaluated the association of serum levels of glycated albumin (GA) and endogenous secretory receptor for advanced glycation end products (esRAGE) with coronary artery remodeling in type 2 diabetic patients.

Methods: Serum levels of GA and esRAGE were measured and intravascular ultrasound was performed in 136 consecutive diabetic patients with 143 coronary intermediate lesions. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-018-0792-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258438PMC
November 2018
16 Reads
4.015 Impact Factor

Does glucagon have a positive inotropic effect in the human heart?

Cardiovasc Diabetol 2018 11 27;17(1):148. Epub 2018 Nov 27.

Departamento de Farmacologia, Facultad de Medicina, Universidad de Murcia Facultad de Medicina, Campus de Espinardo, Espinardo, 30100, Murcia, Spain.

Glucagon is considered to exert cardiostimulant effects, most notably the enhancement of heart rate and contractility, due to the stimulation of glucagon receptors associated with Gs protein stimulation which causes adenylyl cyclase activation and the consequent increase in 3',5'-cyclic adenosine monophosphate production in the myocardium. These effects have been extensively demonstrated in experimental studies in different animal species. However, efforts to extrapolate the experimental data to patients with low cardiac output states, such as acute heart failure or cardiogenic shock, have been disappointing. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-018-0791-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258156PMC
November 2018
11 Reads

Prevalence and in-hospital outcomes of diabetes among patients with acute coronary syndrome in China: findings from the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome Project.

Cardiovasc Diabetol 2018 11 27;17(1):147. Epub 2018 Nov 27.

Department of Epidemiology, Beijing Anzhen Hospital, The Key Laboratory of Remodeling-Related Cardiovascular Diseases, Ministry of Education, Beijing Municipal Key Laboratory of Clinical Epidemiology, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Capital Medical University, No. 2 Anzhen Road, Chaoyang District, Beijing, 100029, China.

Background: Guidelines have classified patients with acute coronary syndrome (ACS) and diabetes as a special population, with specific sections presented for the management of these patients considering their extremely high risk. However, in China up-to-date information is lacking regarding the burden of diabetes in patients with ACS and the potential impact of diabetes status on the in-hospital outcomes of these patients. This study aims to provide updated estimation for the burden of diabetes in patients with ACS in China and to evaluate whether diabetes is still associated with excess risks of early mortality and major adverse cardiovascular and cerebrovascular events (MACCE) for ACS patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0793-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258152PMC
November 2018
1 Read
4.015 Impact Factor

Polyhedrocytes in blood clots of type 2 diabetic patients with high cardiovascular risk: association with glycemia, oxidative stress and platelet activation.

Cardiovasc Diabetol 2018 11 22;17(1):146. Epub 2018 Nov 22.

Institute of Cardiology, Jagiellonian University Medical College, Prądnicka 80 St., Kraków, Poland.

Background: Little is known about factors that affect the composition of contracted blood clots in specific diseases. We investigated the content of polyhedral erythrocytes (polyhedrocytes) formed in blood clots and its determinants in type 2 diabetes (T2D) patients.

Methods: In 97 patients with long-standing T2D [median HbA, 6. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0789-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251112PMC
November 2018
10 Reads

Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?

Cardiovasc Diabetol 2018 11 21;17(1):145. Epub 2018 Nov 21.

Department of Endocrinology and Metabolic Diseases, Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, School of Medicine, Endocrinology and Metabolic Diseases, University of Zagreb, Zagreb, Croatia.

Cardiovascular disease (CVD) is the most significant prognostic factor in individuals with type 2 diabetes (T2D). However, a significant number of individuals may develop CVD that does not present with the classic angina-related or heart failure symptoms. In these cases, CVD may seem to be 'silent' or 'asymptomatic', but may be more accurately characterised as unrecognised diabetic cardiac impairment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0788-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247507PMC
November 2018
17 Reads

A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats.

Cardiovasc Diabetol 2018 11 17;17(1):144. Epub 2018 Nov 17.

Departments of Biophysics, Faculty of Medicine, Ankara University, Ankara, Turkey.

Background: Metabolic syndrome (MetS) is a prevalent risk factor for cardiac dysfunction. Although SGLT2-inhibitors have important cardioprotective effects in hyperglycemia, their underlying mechanisms are complex and not completely understood. Therefore, we examined mechanisms of a SGLT2-inhibitor dapagliflozin (DAPA)-related cardioprotection in overweight insulin-resistant MetS-rats comparison with insulin (INSU), behind its glucose-lowering effect. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-018-0790-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240275PMC
November 2018
8 Reads

Correlations between serum concentration of three bone-derived factors and obesity and visceral fat accumulation in a cohort of middle aged men and women.

Cardiovasc Diabetol 2018 11 13;17(1):143. Epub 2018 Nov 13.

Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital; Shanghai Clinical Center for Diabetes; Shanghai Key Clinical Center for Metabolic Disease; Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, 600 Yishan Road, Shanghai, 200233, China.

Background: The aim of this study was to investigate the interrelationships between three bone-derived factors [serum osteocalcin (OCN), fibroblast growth factor (FGF) 23, and neutrophil gelatinase-associated lipocalin (NGAL) levels] and body fat content and distribution, in order to reveal the potential endocrine function of bone in the development of obesity.

Methods: We recruited 1179 people (aged 59.5 ± 6. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-018-0786-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233377PMC
November 2018
8 Reads

The negative effect of ANGPTL8 on HDL-mediated cholesterol efflux capacity.

Cardiovasc Diabetol 2018 11 8;17(1):142. Epub 2018 Nov 8.

Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, No.139, Middle Renmin Road, Changsha, 410011, Hunan, China.

Background: It is well known that angiopoietin-like protein 8 (ANGPTL8) exerts its effects on lipid metabolism through the inhibition of lipoprotein lipase and subsequent elevation of plasma triglyceride. However, it is not clear whether ANGPTL8 could affect lipid metabolism via other pathways. The study was aimed to investigate the effects of ANGPTL8 on the function of high-density lipoprotein (HDL), which plays a protective role in atherosclerosis progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0785-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223079PMC
November 2018
1 Read

Platelet activity and hypercoagulation in type 2 diabetes.

Cardiovasc Diabetol 2018 11 2;17(1):141. Epub 2018 Nov 2.

Department of Physiological Sciences, Stellenbosch University, Stellenbosch Private Bag X1, Stellenbosch, 7602, South Africa.

Background: A strong correlation exists between type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD), with CVD and the presence of atherosclerosis being the prevailing cause of morbidity and mortality in diabetic populations. T2DM is accompanied by various coagulopathies, including anomalous clot formation or amyloid fibrin(ogen), the presence of dysregulated inflammatory molecules. Platelets are intimately involved in thrombus formation and particularly vulnerable to inflammatory cytokines. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-018-0783-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214175PMC
November 2018
22 Reads

Impact of intravenous exenatide infusion for perioperative blood glucose control on myocardial ischemia-reperfusion injuries after coronary artery bypass graft surgery: sub study of the phase II/III ExSTRESS randomized trial.

Cardiovasc Diabetol 2018 11 1;17(1):140. Epub 2018 Nov 1.

Department of Anesthesiology and Intensive Care Medicine, University Hospital of Besancon, and, EA3920 and SFR-FED 4234 INSERM, University of Franche-Comte, 3 bvd Alexander Fleming, 25000, Besançon, France.

Background: The aim of the study was to investigate whether intravenous (iv) infusion of exenatide, a synthetic GLP-1 receptor agonist, could provide a protective effect against myocardial ischemia-reperfusion injury after coronary artery bypass graft (CABG) surgery.

Methods: A sub study analysis of patients > 18 years admitted for elective CABG and included in the ExSTRESS trial was conducted. Patients were randomized to receive either iv exenatide (1-h bolus of 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0784-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211400PMC
November 2018
6 Reads

Left ventricular subclinical myocardial dysfunction in uncomplicated type 2 diabetes mellitus is associated with impaired myocardial perfusion: a contrast-enhanced cardiovascular magnetic resonance study.

Cardiovasc Diabetol 2018 10 30;17(1):139. Epub 2018 Oct 30.

Department of Radiology, Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, National Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University, 20# South Renmin Road, Chengdu, Sichuan, 610041, China.

Background: Early detection of subclinical myocardial dysfunction in patients with diabetes mellitus (DM) is essential for recommending therapeutic interventions that can prevent or reverse heart failure, thereby improving the prognosis in such patients. This study aims to quantitatively evaluate left ventricular (LV) myocardial deformation and perfusion using cardiovascular magnetic resonance (CMR) imaging in patients with type 2 diabetes mellitus (T2DM), and to investigate the association between LV subclinical myocardial dysfunction and coronary microvascular perfusion.

Methods: We recruited 71 T2DM patients and 30 healthy individuals as controls who underwent CMR examination. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-018-0782-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206833PMC
October 2018
6 Reads

Lower extremity arterial disease in patients with diabetes: a contemporary narrative review.

Cardiovasc Diabetol 2018 10 23;17(1):138. Epub 2018 Oct 23.

Département d'Endocrinologie, Diabétologie, Nutrition, Hôpital Haut-Lévêque, Avenue de Magellan, 33604, Pessac Cedex, France.

Lower-extremity arterial disease (LEAD) is a major endemic disease with an alarming increased prevalence worldwide. It is a common and severe condition with excess risk of major cardiovascular events and death. It also leads to a high rate of lower-limb adverse events and non-traumatic amputation. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-018-0781-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198374PMC
October 2018
12 Reads

Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate.

Cardiovasc Diabetol 2018 10 22;17(1):137. Epub 2018 Oct 22.

Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania "Luigi Vanvitelli", Piazza Miraglia, 2, 80138, Naples, Italy.

Objectives: To evaluate clinical outcomes in patients with diabetes, treated by cardiac resynchronization therapy with a defibrillator (CRT-d), and glucagon-like peptide 1 receptor agonists (GLP-1 RA) in addition to conventional hypoglycemic therapy vs. CRTd patients under conventional hypoglycemic drugs.

Background: Patients with diabetes treated by CRTd experienced an amelioration of functional New York Association Heart class, reduction of hospital admissions, and mortality, in a percentage about 60%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0778-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196445PMC
October 2018
8 Reads

Hyperglycemia and risk of ventricular tachycardia among patients hospitalized with acute myocardial infarction.

Cardiovasc Diabetol 2018 10 19;17(1):136. Epub 2018 Oct 19.

Department of Quantitative Health Sciences, University of Massachusetts Medical School, 368 Plantation Street, Worcester, MA, 01605, USA.

Background: Little is known about the association of hyperglycemia with the development of ventricular tachycardia (VT) in patients hospitalized with acute myocardial infarction (AMI) which we examined in the present study. The objectives of this community-wide observational study were to examine the relation between elevated serum glucose levels at the time of hospital admission for AMI and occurrence of VT, and time of occurrence of VT, during the patient's acute hospitalization.

Methods: We used data from a population-based study of patients hospitalized with AMI at all central Massachusetts medical centers between 2001 and 2011. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0779-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194566PMC
October 2018
1 Read

Impact of type 2 diabetes mellitus in the utilization and in-hospital outcomes of surgical aortic valve replacement in Spain (2001-2015).

Cardiovasc Diabetol 2018 10 16;17(1):135. Epub 2018 Oct 16.

Preventive Medicine and Public Health Teaching and Research Unit, Health Sciences Faculty, Rey Juan Carlos University, Alcorcón, Madrid, Spain.

Background: The aims of this study were to examine trends in the incidence and in-hospital outcomes of SAVR among T2DM patients from 2001 to 2015, to compare clinical variables among T2DM patients and matched non-T2DM patients hospitalized for SAVR and to identify factors associated with in-hospital mortality (IHM) among T2DM patients.

Methods: We performed a retrospective study using the Spanish National Hospital Discharge Database, 2001-2015. We included patients who had SAVR as the procedure in their discharge report. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0780-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190659PMC
October 2018
1 Read

Perivascular adipose tissue (PVAT) in atherosclerosis: a double-edged sword.

Cardiovasc Diabetol 2018 10 10;17(1):134. Epub 2018 Oct 10.

Institute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan Province, University of South China, Hengyang, 421001, China.

Perivascular adipose tissue (PVAT), the adipose tissue that surrounds most of the vasculature, has emerged as an active component of the blood vessel wall regulating vascular homeostasis and affecting the pathogenesis of atherosclerosis. Although PVAT characteristics resemble both brown and white adipose tissues, recent evidence suggests that PVAT develops from its own distinct precursors implying a closer link between PVAT and vascular system. Under physiological conditions, PVAT has potent anti-atherogenic properties mediated by its ability to secrete various biologically active factors that induce non-shivering thermogenesis and metabolize fatty acids. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0777-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180425PMC
October 2018
2 Reads

Rising plasminogen activator inhibitor-1 and hypoadiponectinemia characterize the cardiometabolic biomarker profile of women with recent gestational diabetes.

Cardiovasc Diabetol 2018 10 9;17(1):133. Epub 2018 Oct 9.

Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, 60 Murray Street, Suite-L5-039, Mailbox-21, Toronto, ON, M5T3L9, Canada.

Background: Gestational diabetes (GDM) and milder gestational impaired glucose tolerance (GIGT) identify women at risk of developing type 2 diabetes and cardiovascular disease later in life. Accordingly, the postpartum years after gestational dysglycemia can provide insight into early events in the natural history of these disorders. We thus sought to prospectively evaluate the relationship between gestational glucose tolerance and emerging cardiometabolic biomarkers [adiponectin, chemerin, retinol-binding protein-4 (RBP-4), C-reactive protein (CRP), plasminogen activator inhibitor-1 (PAI-1)] at both 1- and 3-years postpartum in a cohort reflecting the full spectrum of gestational dysglycemia (from normal to GIGT to GDM). Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-018-0776-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176527PMC
October 2018
13 Reads

Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.

Cardiovasc Diabetol 2018 10 8;17(1):132. Epub 2018 Oct 8.

Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.

Background: The objective of this study was to investigate the impact of sodium glucose cotransporter type 2 (SGLT2) inhibitors on left ventricular (LV) diastolic function of type 2 diabetes mellitus (T2DM) patients with heart failure (HF).

Methods: This trial was a prospective multicenter study of 58 T2DM patients with stable HF at five institutions in Japan. Patients who had been taking at least one antidiabetic drugs other than SGLT2 inhibitors started the administration of 5 mg/day of dapagliflozin. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-018-0775-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174555PMC
October 2018
2 Reads

Impaired glucose metabolism is associated with increased thrombin generation potential in patients undergoing angioplasty and stenting.

Cardiovasc Diabetol 2018 09 29;17(1):131. Epub 2018 Sep 29.

Department of Internal Medicine II, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.

Background: As a strong platelet agonist on the one hand and key molecule in plasmatic coagulation on the other hand, thrombin connects primary and secondary hemostasis. Thrombin generation potential reflects the individual capacity to generate thrombin, and has been associated with the occurrence of thromboembolic events. In the current study, we sought to identify predictors of thrombin generation potential in patients undergoing angioplasty and stenting for atherosclerotic cardiovascular disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0774-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162876PMC
September 2018
2 Reads

Both pre-frailty and frailty increase healthcare utilization and adverse health outcomes in patients with type 2 diabetes mellitus.

Cardiovasc Diabetol 2018 09 27;17(1):130. Epub 2018 Sep 27.

Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, No. 1, Sec. 4, Roosevelt Road, Taipei, 10617, Taiwan.

Background: Diabetes mellitus (DM) correlates with accelerated aging and earlier appearance of geriatric phenotypes, including frailty. However, whether pre-frailty or frailty predicts greater healthcare utilization in diabetes patients is unclear.

Methods: From the Longitudinal Cohort of Diabetes Patients in Taiwan (n = 840,000) between 2004 and 2010, we identified 560,795 patients with incident type 2 DM, categorized into patients without frailty, or with 1, 2 (pre-frail) and ≥ 3 frailty components, based on FRAIL scale (Fatigue, Resistance, Ambulation, Illness, and body weight Loss). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0772-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158921PMC
September 2018
12 Reads

Effects of oral antidiabetic drugs on left ventricular mass in patients with type 2 diabetes mellitus: a network meta-analysis.

Cardiovasc Diabetol 2018 09 27;17(1):129. Epub 2018 Sep 27.

Department of Diabetes and Metabolism, Ise Red Cross Hospital, 1-471-2, Funae, 1-chome, Ise-shi, Mie, 516-8512, Japan.

Background: We used a network meta-analysis of randomized controlled trials (RCTs) to comparatively examine the effects of oral antidiabetic drugs (OADs) on left ventricular mass (LVM) in patients with type 2 diabetes.

Methods: Document searches were implemented using Medline, Cochrane Controlled Trials Registry, and ClinicalTrials.gov. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0773-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158875PMC
September 2018
3 Reads